Thamer H. Alenazi

Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone Resistance

Patrick N. A. Harris, Paul Anantharajah Tambyah, David Chien Lye et al. · JAMA · 2018 · 770 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +16

Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study

Jinnethe Reyes, Lauren Komarow, Liang Chen et al. · The Lancet Microbe · 2023 · 291 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study

Andrew Henderson, David L. Paterson, Mark D. Chatfield et al. · Clinical Infectious Diseases · 2020 · 158 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +15

Prevalence and predictors of anxiety among healthcare workers in Saudi Arabia during the COVID-19 pandemic

Thamer H. Alenazi, Nasser F. BinDhim, Meteb H. Alenazi et al. · Journal of Infection and Public Health · 2020 · 134 citations · Full text

Health Professions, Health Sciences, Behavioral Epidemiology +12

Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant <i>Acinetobacter baumannii</i> Among Patients From Different Global Regions

Minggui Wang, Lizhao Ge, Liang Chen et al. · Clinical Infectious Diseases · 2023 · 94 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +16